Cytoplasmic translocation of p21 mediates NUPR1-induced chemoresistance: NUPR1 and p21 in chemoresistance

FEBS Letters

Volumn 586, Issue 19, 2012, Pages 3429-3434

  Vincent, Andrew J ^a   Ren, Suping ^a   Harris, Lillianne G ^a   Devine, Daniel J ^a   Samant, Rajeev S ^b,c   Fodstad, Oystein ^d,e   Shevde, Lalita A ^b,c  

^a UNIVERSITY OF SOUTH ALABAMA   (United States)

^b University of Alabama at Birmingham   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d OSLO UNIVERSITY HOSPITAL   (Norway)

^e UNIVERSITY OF OSLO   (Norway)

Author keywords

Akt; Chemoresistance; IKK ; NUPR1; P21

Indexed keywords

DOXORUBICIN; I KAPPA B KINASE BETA; NUCLEAR PROTEIN; NUCLEAR PROTEIN 1; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BCL XL; PROTEIN KINASE B; PROTEIN P21; PROTEIN P53; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CONTROLLED STUDY; CYTOPLASM; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; TRIPLE NEGATIVE BREAST CANCER;

BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; BCL-X PROTEIN; BIOLOGICAL TRANSPORT, ACTIVE; BREAST NEOPLASMS; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYTOPLASM; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; NEOPLASM PROTEINS; NUCLEAR PROTEINS; ONCOGENE PROTEIN V-AKT; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84866619153     PISSN: 00145793     EISSN: 18733468     Source Type: Journal    
DOI: 10.1016/j.febslet.2012.07.063     Document Type: Article

References (44)

1. G.N. Hortobagyi, W. Heim, L. Hutchins, E. Rivera, B. Mason, D.J. Booser, and J. Kirshner A phase 2 study of a fixed combination of uracil and ftorafur (UFT) and leucovorin given orally in a 3-times-daily regimen to treat patients with recurrent metastatic breast cancer Cancer 116 2010 1440 1445
2. M. Castiglione-Gertsch, and The International Breast Cancer Study Group Retreating recurrent breast cancer with the same CMF-containing regimen used as adjuvant therapy Eur. J. Cancer 33 1997 2321 2325
3. V. Giroux, C. Malicet, M. Barthet, M. Gironella, C. Archange, J.C. Dagorn, S. Vasseur, and J.L. Iovanna p8 is a new target of gemcitabine in pancreatic cancer cells Clin. Cancer Res. 12 2006 235 241
4. S.B. Su Expression of p8 in human pancreatic cancer Clin. Cancer Res. 7 2001 309 313
5. A.H. Ree Clinical and cell line specific expression profiles of a human gene identified in experimental central nervous system metastases Anticancer Res. 22 2002 1949 1957
6. Y. Ito Expression and cellular localization of p8 protein in thyroid neoplasms Cancer Lett. 201 2003 237 244
7. H.P. Mohammad, D.D. Seachrist, C.C. Quirk, and J.H. Nilson Reexpression of p8 contributes to tumorigenic properties of pituitary cells and appears in a subset of prolactinomas in transgenic mice that hypersecrete luteinizing hormone Mol. Endocrinol. 18 2004 2583 2593
8. D.K. Kong, S.P. Georgescu, C. Cano, M.J. Aronovitz, J.L. Iovanna, R.D. Patten, J.M. Kyriakis, and S. Goruppi Deficiency of the transcriptional regulator p8 results in increased autophagy and apoptosis, and causes impaired heart function Mol. Biol. Cell 21 2010 1335 1349
9. D.W. Clark, A. Mitra, R.A. Fillmore, W.G. Jiang, R.S. Samant, O. Fodstad, and L.A. Shevde NUPR1 interacts with p53, transcriptionally regulates p21 and rescues breast epithelial cells from doxorubicin-induced genotoxic stress Curr. Cancer Drug Targets 8 2008 421 430
10. A.H. Ree Expression of a novel factor in human breast cancer cells with metastatic potential Cancer Res. 59 1999 4675 4680
11. M.J. Sandi, T. Hamidi, C. Malicet, C. Cano, C. Loncle, A. Pierres, J.C. Dagorn, and J.L. Iovanna p8 expression controls pancreatic cancer cell migration, invasion, adhesion, and tumorigenesis J. Cell Physiol. 226 2011 3442 3451
12. M. Asada, T. Yamada, H. Ichijo, D. Delia, K. Miyazono, K. Fukumuro, and 5. Mizutani Apoptosis inhibitory activity of cytoplasmic p21(Cip1/WAF1) in monocyticdifferentiation EMBO J. 18 1999 1223 1234
13. M.V. Blagosklonny Are p27 and p21 cytoplasmic oncoproteins? Cell Cycle 1 2002 391 393
14. J.W. Harper Inhibition of cyclin-dependent kinases by p21 Mol. Biol. Cell 6 1995 387 400
15. H. Flores-Rozas, Z. Kelman, F.B. Dean, Z.Q. Pan, J.W. Harper, S.J. Elledge, M. O'Donnell, and J. Hurwitz Cdk-interacting protein 1 directly binds with proliferating cell nuclear antigen and inhibits DNA replication catalyzed by the DNA polymerase delta holoenzyme Proc. Natl. Acad. Sci. USA 91 1994 8655 8659
16. J. Zhan, J.B. Easton, S. Huang, A. Mishra, L. Xiao, E.R. Lacy, R.W. Kriwacki, and P.J. Houghton Negative regulation of ASK1 by p21Cip1 involves a small domain that includes Serine 98 that is phosphorylated by ASK1 in vivo Mol. Cell. Biol. 27 2007 3530 3541
17. K. Yamamoto, H. Ichijo, and S.J. Korsmeyer BCL-2 is phosphorylated and inactivated by an ASK1/Jun N-terminal protein kinase pathway normally activated at G(2)/M Mol. Cell. Biol. 19 1999 8469 8478
18. M. Wasielewski, F. Elstrodt, J.G. Klijn, E.M. Berns, and M. Schutte Thirteen new p53 gene mutants identified among 41 human breast cancer cell lines Breast Cancer Res. Treat. 99 2006 97 101
19. K.A. Morrow, S. Das, B.J. Metge, K. Ye, M.S. Mulekar, J.A. Tucker, R.S. Samant, and L.A. Shevde Loss of tumor suppressor Merlin in advanced breast cancer is due to post-translational regulation J. Biol. Chem. 286 2011 40376 40385
20. S. Vasseur, G. Vidal Mallo, F. Fiedler, H. Bodeker, E. Canepa, S. Moreno, and J.L. Iovanna Cloning and expression of the human p8, a nuclear protein with mitogenic activity Eur. J. Biochem. 259 1999 670 675
21. Y.F. Jiang, M.I. Vaccaro, F. Fiedler, E.L. Calvo, and J.L. Iovanna Lipopolysaccharides induce p8 mRNA expression in vivo and in vitro Biochem. Biophys. Res. Commun. 260 1999 686 690
22. B.P. Zhou, Y. Liao, W. Xia, B. Spohn, M.H. Lee, and M.C. Hung Cytoplasmic localization of p21Cip1/WAF1 by Akt-induced phosphorylation in HER- 2/neu-overexpressing cells Nat. Cell. Biol. 3 2001 245 252
23. W. Xia, J.S. Chen, X. Zhou, P.R. Sun, D.F. Lee, Y. Liao, B.P. Zhou, and M.C. Hung Phosphorylation/cytoplasmic localization of p21Cip1/WAF1 is associated with HER2/neu overexpression and provides a novel combination predictor for poor prognosis in breast cancer patients Clin. Cancer Res. 10 2004 3815 3824
24. L. Yuste, J.C. Montero, A. Esparis-Ogando, and A. Pandiella Activation of ErbB2 by overexpression or by transmembrane neuregulin results in differential signaling and sensitivity to herceptin Cancer Res. 65 2005 6801 6810
25. G. Perez-Tenorio, F. Berglund, A. Esguerra Merca, B. Nordenskjold, L.E. Rutqvist, L. Skoog, and O. Stal Cytoplasmic p21WAF1/CIP1 correlates with Akt activation and poor response to tamoxifen in breast cancer Int. J. Oncol. 28 2006 1031 1042
26. C. Heliez, L. Baricault, N. Barboule, and A. Valette Paclitaxel increases p21 synthesis and accumulation of its AKT-phosphorylated form in the cytoplasm of cancer cells Oncogene 22 2003 3260 3268
27. B. Ping Cytoplasmic expression of p21CIP1/WAF1 is correlated with IKKbeta overexpression in human breast cancers Int. J. Oncol. 29 2006 1103 1110
28. M. Upreti, E.N. Galitovskaya, R. Chu, A.J. Tackett, D.T. Terrano, S. Granell, and T.C. Chambers Identification of the major phosphorylation site in Bcl-xL induced by microtubule inhibitors and analysis of its functional significance J. Biol. Chem. 283 2008 35517 35525
29. J.K. Park, C.H. Cho, S. Ramachandran, S.J. Shin, S.H. Kwon, S.Y. Kwon, and S.D. Cha Augmentation of sodium butyrate-induced apoptosis by phosphatidylinositol 3-kinase inhibition in the human cervical cancer cell-line Cancer Res. Treat. 38 2006 112 117
30. Y. Li, D. Dowbenko, and L.A. Lasky AKT/PKB phosphorylation of p21Cip/WAF1 enhances protein stability of p21Cip/WAF1 and promotes cell survival J. Biol. Chem. 277 2002 11352 11361
31. G.V. Mallo, F. Fiedler, E.L. Calvo, E.M. Ortiz, S. Vasseur, V. Keim, J. Morisset, and J.L. Iovanna Cloning and expression of the rat p8 cDNA, a new gene activated in pancreas during the acute phase of pancreatitis, pancreatic development, and regeneration, and which promotes cellular growth J. Biol. Chem. 272 1997 32360 32369
32. W.G. Jiang, G. Davies, and O. Fodstad Com-1/P8 in oestrogen regulated growth of breast cancer cells, the ER-beta connection Biochem. Biophys. Res. Commun. 330 2005 253 262
33. S. Vasseur p8 improves pancreatic response to acute pancreatitis by enhancing the expression of the anti-inflammatory protein pancreatitis- associated protein I J. Biol. Chem. 279 2004 7199 7207
34. A. Suzuki, Y. Tsutomi, K. Akahane, T. Araki, and M. Miura Resistance to Fas-mediated apoptosis: activation of caspase 3 is regulated by cell cycle regulator p21WAF1 and IAP gene family ILP Oncogene 17 1998 931 939
35. Z.E. Winters, N.C. Hunt, M.J. Bradburn, J.A. Royds, H. Turley, A.L. Harris, and C.J. Norbury Subcellular localisation of cyclin B, Cdc2 and p21(WAF1/CIP1) in breast cancer association with prognosis Eur. J. Cancer 37 2001 2405 2412
36. M. Malumbres, and M. Barbacid Is Cyclin D1-CDK4 kinase a bona fide cancer target? Cancer Cell 9 2006 2 4
37. M. Varna, G. Bousquet, L.F. Plassa, P. Bertheau, and A. Janin TP53 status and response to treatment in breast cancers J. Biomed. Biotechnol. 2011 284584
38. A. Hollestelle Distinct gene mutation profiles among luminal-type and basal-type breast cancer cell lines Breast Cancer Res. Treat. 121 2010 53 64
39. R.A. Campbell, P. Bhat-Nakshatri, N.M. Patel, D. Constantinidou, S. Ali, and H. Nakshatri Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance J. Biol. Chem. 276 2001 9817 9824
40. G. Perez-Tenorio, and O. Stal Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients Br. J. Cancer 86 2002 540 545
41. A. Shah Phospho-akt expression is associated with a favorable outcome in non-small cell lung cancer Clin. Cancer Res. 11 2005 2930 2936
42. A.M. Bleau, D. Hambardzumyan, T. Ozawa, E.I. Fomchenko, J.T. Huse, C.W. Brennan, and E.C. Holland PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells Cell Stem Cell 4 2009 226 235
43. T. Sinnberg Inhibition of PI3K-AKT-mTOR signaling sensitizes melanoma cells to cisplatin and temozolomide J. Invest. Dermatol. 129 2009 1500 1515
44. J.Q. Cheng, C.W. Lindsley, G.Z. Cheng, H. Yang, and S.V. Nicosia The Akt/PKB pathway: molecular target for cancer drug discovery Oncogene 24 2005 7482 7492